linjc16/ctgov huggingface dataset:
Hypertensive Disorders of Pregnancy in Adolescence and Primipaternity

Study Overview
=================
Brief Summary
-----------------
Hypertensive disorders of pregnancy are one of the most frequent complications of pregnancy, being a serious health problem around the world. Previous studies have suggested that there is an association between a short period of exposure to paternal sperm of a new sexual partner and the development of an immunological reaction that could trigger a hypertensive disorder of pregnancy. For this reason we want to study the relationship between the primipaternity concept (exposure to male antigens present in semen over a short period of time previous to the pregnancy) and the development of preeclampsia in adolescents.

Official Title
-----------------
Hypertensive Disorders of Pregnancy in Adolescence and the Primipaternity Concept. Cases and Control Trial

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 19 year old or less Pregnancy > 24 weeks at the moment of delivery Exclusion Criteria: 20 years old or more. Pregnancy < 24 weeks at the moment of delivery

Ages Eligible for Study
-----------------
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adolescent with preeclampsia<br>Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy. | |
| Normal adolescent<br>Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of a primipaternity factor | The presence of primipaternity factor. They include: Sexual Cohabitation (timeframe between first sexual intercourse and pregnancy < 4 months)without the use of a barrier contraceptive. Oral sex with ejaculation (previous to pregnancy < 4 months). | Two months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal complications | Presence of a complication related to preeclampsia: abruptio placenta, HELLP syndrome, eclampsia. | Two months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preeclampsia in Adolescence, Adolescent, Primipaternity
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.

Detailed Description
-----------------
This Pfizer run study stopped due to the co-development program for indiplon being terminated between Pfizer and Neurocrine. The study was terminated on 16 November 2006. There were no safety issues leading to the decision to terminate this study.

Official Title
-----------------
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Tolerability Of Indiplon Therapy Initiated With Sertraline Versus Sertraline Monotherapy In Subjects With Insomnia And Co-Existing Major Depressive Disorder

Conditions
-----------------
Insomnia, Depression

Intervention / Treatment
-----------------
* Drug: Indiplon
* Drug: Sertraline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV defined insomnia DSM-IV defined Major Depression Exclusion Criteria: Current suicidal ideation or behavior Primary sleep disorder other than insomnia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Indiplon|nan|
|Drug: Sertraline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline to week 1 in subjective total sleep time (sTST); (average of the week one data) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in subjective total sleep time (sTST). Change from baseline in subjective parameters: LSO, sWASO, sNAASO, Sleep Quality (IVR). Change from baseline in the 3-item HAM-D insomnia factor (items #4-6). |  |  |
Patient-controlled Sedation With Propofol During Cataract Surgery Under Topical Anesthesia

Study Overview
=================
Brief Summary
-----------------
Controversies exist about the use of propofol in sedation of patients for cataract surgery. This prospective randomised double-blind study evaluates the efficacy of patient-controlled sedation compared with placebo using the same device.

Official Title
-----------------
Randomised Study of Propofol Versus Placebo for Sedation During Cataract Surgery Under Topical Anesthesia

Conditions
-----------------
Sedation

Intervention / Treatment
-----------------
* Drug: Propofol
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients should be operated of cataract under topical anesthesia Exclusion Criteria: Contra-indication to sedation Complicated cataract Hypersensitivity to propofol, known or suspected hypersensitivity to egg phospholipid, soybean or peanut protein State of acute shock, severe dyslipidemia, severe liver failure, serious bleeding disorders Comprehension and language impairment Written and signed informed consent by the patient to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Propofol<br>Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %). Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes. Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h. | Drug: Propofol<br>* Propofol and excipients<br>* Other names: Propofol lipuro 2%;|
| Placebo Comparator: Intralipid<br>Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion. Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes. | Drug: Placebo<br>* Qualitative composition of Propofol lipuro 2% excipients<br>* Other names: Intralipid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of self administered bolus |  | One day |
Incidence and Management of Ocular Hypertension Following Deep Anterior Lamellar Keratoplasty

Study Overview
=================
Brief Summary
-----------------
This is a retrospective case series study that included patients who performed deep anterior lamellar keratoplasty and presented with elevated intraocular pressure during follow up.

Detailed Description
-----------------
This is a retrospective case series study that included patients who performed deep anterior lamellar keratoplasty and presented with elevated intraocular pressure during follow up. Patients' demographic characteristics, medical, and ocular history will be recorded. Inclusion criteria will include patients who were diagnosed with elevated intraocular pressure (IOP) after DALK surgery performed from 2018 to 2020 with follow up duration more than 6 months. Patients with less than 6 months of follow-up will be excluded from the study. Patients' demographic characteristics, medical and ocular history will be recorded. Baseline complete ophthalmic examination was performed. It included best corrected visual acuity (BCVA) using Landolt C chart that was converted to log minimum angle of resolution (log MAR) for statistical analysis, slit lamp anterior segment examination (with attention to cornea, bulbar conjunctiva and AC), intraocular pressure measurement using rebound system (I care tonometer, Topcon, Canada), angle assessment and fundus examination using Goldman 3 mirror contact lens. High IOP was defined as intraocular pressure more than 25 mmHg. Data will be collected with attention to appropriate management done either medical treatment or surgical intervention.

Official Title
-----------------
Incidence and Management of Ocular Hypertension Following Deep Anterior Lamellar Keratoplasty

Conditions
-----------------
Unrecognized Condition

Intervention / Treatment
-----------------
* Other: antiglaucoma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who were diagnosed with elevated IOP after DALK surgery performed from 2018 to 2020 Exclusion Criteria: Patients with penetrating keratoplasty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: antiglaucoma|use antiglaucoma in ocular hypertension|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure values | assessment of intraocular pressure after lamellar keratoplasty | this is a retrospective study . collection of data from patients records over 2 months |
Investigation of Hepatitis B and Hepatitis C in Taiwan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the differences of genotypes of hepatitis B and hepatitis C in Taiwan.

Detailed Description
-----------------
The purpose of this study is investigating the differences of genotypes and DNA level or RNA level of hepatitis B and hepatitis C in Taiwan.

Official Title
-----------------
Investigation of Hepatitis B and Hepatitis C in Taiwan

Conditions
-----------------
Hepatitis B, Hepatitis C

Intervention / Treatment
-----------------
* Biological: blood sampling and abdominal sonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Born before 1985/01/01 HBV or HCV carriers Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan | Biological: blood sampling and abdominal sonography<br>* 10cc blood sampling and abdominal sonography<br>* Other names: 10cc blood sampling and abdominal sonography;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genotype and DNA level or RNA level of HBV and HCV virus |  | once during Mar. 2008- Jan. 2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RNA level, Hepatitis B, Hepatitis C, genotype, DNA level, Taiwan
Study on the Geometric Parameters and Hemodynamic Reference Range of Neonatal Heart.

Study Overview
=================
Brief Summary
-----------------
Perform bedside echocardiography on neonates (term and preterm infants) who were admitted to our neonatal department within 24 hours of birth, and establish a geometric reference range of neonatal cardiac ultrasound and explore the hemodynamic changes of early newborns. Bedside echocardiography were performed to measure the diameter of each heart cavity and large vessels, velocity of each valve and aorta, wall thickness, left ventricular systolic function, right heart Tei index, Tricuspid Annular Plane Systolic Excursion(TPASE) of term and preterm infants respectively on 0 day, 3d, 7d of life and postmenstrual age of 30 weeks, 32 weeks, 34 weeks and 36 weeks.

Official Title
-----------------
Prospective Study on Geometric Parameters and Hemodynamic Reference Range of Neonatal Heart.

Conditions
-----------------
Echocardiography of Newborns

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Infants with normal hearts (infants with small patent fora-men oval or small patent ductus arteriosus were not excluded). 2.Healthy preterm infant with no evidence of sepsis, renal failure. 3. Absence of other major congenital anomalies or syndromes 4. Prior written consent was obtained from the parents. Exclusion Criteria: Infants with severe congenital malformations, either cardiac or non-cardiac.

Ages Eligible for Study
-----------------
Maximum Age: 12 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| postnatal age<br> | |
| General information and echocardiographic data<br>General information:(1)Record the gestational age, birth weight, length, delivery way, Apgar score, maternal pregnancy status, prenatal bleeding or not after admission.(2)PS use, ventilator mode, other illness and complications should be recorded during hospitalization. (3) Record the baby's heart rate, respiratory rate, blood pressure, body surface area on every check. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reference range of cardiac geometric parameters of preterm infants based on different gestational ages, weights, days of age and body surface area. |  | 0 day of life to PMA 36 weeks | 
| Hemodynamic changes in full-term and preterm infants on 0 7days of life. |  | 0 7days of life | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reference range of cardiac geometric parameters of full-term infants based on different weights, days of age and body surface area. |  | 0 7days of life | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Echocardiography, Heart, Neonatal, Reference range
Liposuction as Treatment for Excessive Axillary Sweat

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if suction-curettage of the axilla is favorable in regard to effect, recovery and cosmetic appearance compared to standard surgical excision of the skin of the axilla in case of excessive sweating.

Detailed Description
-----------------
The surgical standard treatment for isolated excessive axillary sweating is excision of the hair-bearing area of the axilla. This technique is associated with a risk of impaired wound healing, infections, wide scars and a risk of impairment in the movement of the arm (seldom). A new technique suction-curettage, much alike the liposuction technique, in which the dermis is curettage from a sub-dermal approach with a cutting and sucking devise, may be promising in regard to recovery and cosmetic appearance postoperatively, but the effect of the sweat production is not well known. This study compares liposuction vs. standard excision in individuals with isolated excessive isolated axillary sweating randomized to treatment with one of each technique in both axillas.

Official Title
-----------------
Suction-Curettage vs. Standard Excision in Axillary Hyperhidrosis

Conditions
-----------------
Hyperhidrosis

Intervention / Treatment
-----------------
* Procedure: Suction-curettage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult individuals with primary axillary hyperhidrosis Exclusion Criteria: Secondary axillary hyperhidrosis Hidrosadenitis axillaris/inguinalis Prior surgery Iontophoresis or botox treatment 12 months prior Known hypersensitivity to local analgetics (lidocaine)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Suction-curettage|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperhidrosis, Axillary, Excision, Suction-curettage, Outcome
Patient-reported Outcome After Sling Insertion Using the Incontinence Outcome Questionnaire (IOQ)

Study Overview
=================
Brief Summary
-----------------
Midurethral tapes are by now standard procedure in the surgical treatment of women with stress urinary incontinence. While the retropubic TVT is well documented with long-term results up to 11 years and continence rates of 90 %, the published data for the transoburator tapes (TO) cover follow-up of 3 years only. So far, all tapes establish continence effectively. Recently, the detailed 27-item Incontinence Outcome Questionnaire (IOQ) was constructed to assess patient-reported outcome and quality of life after insertion of a midurethral tape and validated for the German language. The aim of this study was to evaluate patient-reported mid- and long-term outcome after insertion of tension-free vaginal tape (TVT), transobturator sling, outside-in (TOT) and tension-free transobturator tape, inside-out (TVT-O).

Official Title
-----------------
Patient-reported Mid- and Long-term Outcome After Insertion of Retropubic and Transobturator Tapes Using the Incontinence Outcome Questionnaire (IOQ)

Conditions
-----------------
Stress Urinary Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: incontinence sling time frame 1/1999 - 12/2007

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TOT<br>transobturator sling, outside-in (TOT) | |
| TVT-O<br>Tension-free transobturator tape, inside-out (TVT-O) | |
| IVS<br>retropubic Intravaginal Sling (IVS) | |
| TVT<br>retropubic tension-free vaginal tape (TVT) | |
| REMEEX<br>Re-adjustable mechanical external sling (REMEEX) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient's satisfaction |  | 3/2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| re-admission |  | 3/2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stress urinary incontinence, retropubic sling, transobturator sling, tension-free vaginal tape, transobturator tape, TVT, TVT-O, TOT, REMEEX, IVS
Feasibility Study of a Temporary Peripheral Nerve Stimulator

Study Overview
=================
Brief Summary
-----------------
A novel temporary peripheral nerve stimulator will be evaluated for safety, usability, and preliminary efficacy.

Official Title
-----------------
Feasibility Study of a Temporary Peripheral Nerve Stimulator

Conditions
-----------------
Nerve Injury

Intervention / Treatment
-----------------
* Device: Temporary Peripheral Nerve Stimulator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Are between 18-65 years old Have a Sunderland II-V peripheral nerve injury of the upper extremity Are receiving surgery within 14 days of injury Exclusion Criteria: Nerve plexus injuries (e.g. brachial plexus) Nerve gap requiring graft/conduit, or extreme joint flexion Polyneuropathies Cognitive impairment and non-English-speaking Uncontrolled diabetes Surgical intervention > 14 days of injury Co-enrollment in another clinical trial Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Device Usability<br>Device usability and safety will be evaluated. | Device: Temporary Peripheral Nerve Stimulator<br>* Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.<br>|
| Experimental: Preliminary Efficacy<br>Preliminary treatment efficacy will be evaluated. | Device: Temporary Peripheral Nerve Stimulator<br>* Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Tolerance to Therapy Questionnaire |  | Immediately after procedure | 
| Static Two Point Discrimination | Measurement of spatial determination | 6 months | 
| Semmes-Weinstein Monofilament Test | Measurement of pressure sensitivity | 6 months | 
| DASH Questionnaire | Validated questionnaire for functionality in upper extremity injury | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety | As measured by the cumulative incidence of adverse events. | 6 months | 
| Device Usability Questionnaire |  | Immediately after procedure |